Oncology – Page 9

Adjunctive SGLT2 Inhibitors with Progestins Reduce Endometrial Cancer Risk in Benign Uterine Conditions: Insights from a Large Real-World Study

By MedXY 07/08/2026

A large retrospective study demonstrates that adding SGLT2 inhibitors to progestin therapy in women with benign uterine diseases reduces the risk of developing endometrial cancer and the need for hysterectomy.

Gastroenterology news Oncology

Targeting SMPD1-Driven Sphingolipid Metabolism to Disrupt KRAS Signaling in Pancreatic Ductal Adenocarcinoma

By MedXY 07/08/2026

This study reveals that dysregulated sphingolipid metabolism via SMPD1 supports KRAS-driven pancreatic cancer progression, identifying SMPD1 as a promising therapeutic target in pancreatic ductal adenocarcinoma.

Clinical Updates Gastroenterology news Oncology Pathology & Lab Medicine

Circulating Methylated SEPT9 as a Novel Biomarker for Early Detection of Hepatocellular Carcinoma in Cirrhotic Patients

By MedXY 07/07/2026

Combining circulating methylated SEPT9 with alpha-fetoprotein significantly enhances early hepatocellular carcinoma detection in cirrhotic patients, outperforming AFP alone and allowing improved surveillance sensitivity and specificity.

news Oncology Otorhinolaryngology

Elevated Blood Manganese Linked to Increased Risk of Head and Neck Squamous Cell Carcinomas: Insights from Mendelian Randomization

By MedXY 07/05/2026

A genetic study reveals that higher blood manganese levels are significantly associated with increased risks of oral cavity and HPV-positive oropharyngeal squamous cell carcinomas, suggesting a novel biomarker and potential target for prevention strategies in head and neck cancers.

General Surgery news Oncology

Reevaluating Lumpectomy Margin Thresholds in HR-Positive DCIS: Insights from the NRG Oncology/NSABP B-35 Trial

By MedXY 07/05/2026

This study evaluates the impact of lumpectomy margin widths on local recurrence in postmenopausal women with hormone receptor-positive DCIS undergoing lumpectomy, radiation, and endocrine therapy, suggesting minimal recurrence differences below 1-2 mm margins.

news Oncology Radiology

Advancing Precision Prognosis in High-Grade Serous Ovarian Cancer via Multi-Time Point Radiomics and Clinical Data Integration

By MedXY 07/05/2026

This study demonstrates that combining clinical variables with computed tomography radiomics features improves the prediction of recurrence-free survival in high-grade serous ovarian cancer patients undergoing neoadjuvant chemotherapy and surgery.

Gastroenterology news Oncology

Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver Metastases

By MedXY 07/04/2026

This study reveals that circulating tumor DNA (ctDNA) status after colorectal liver metastasis surgery predicts survival outcomes and benefits from adjuvant chemotherapy, guiding personalized treatment.

news OB/GYN & Women’s Health Oncology

Global Variations in Concurrent Hysterectomy During Risk-Reducing Surgery for BRCA1/2 Carriers: An Integrated Quantitative and Qualitative Analysis

By MedXY 07/03/2026

This study reveals significant international differences in concurrent hysterectomy rates during risk-reducing salpingo-oophorectomy among BRCA1/2 variant carriers and explores underlying factors influencing surgical decisions across regions.

news Oncology Respiratory

Symptom Prevalence in Lung Cancer Screening: Insights from the SUMMIT Study

By MedXY 07/02/2026

The SUMMIT study reveals that respiratory symptoms are common among lung cancer screening participants and associated with increased lung cancer diagnosis risk within one year, challenging conventional asymptomatic screening definitions.

news OB/GYN & Women’s Health Oncology

Laparoscopic HIPEC as Consolidation Therapy in Advanced Epithelial Ovarian Cancer: Feasibility and Impact on Quality of Life

By MedXY 07/01/2026

Laparoscopic HIPEC following upfront treatment in advanced epithelial ovarian cancer is feasible, safe, and preserves patient quality of life, offering a promising consolidation approach.

Gastroenterology news Oncology

Helicobacter pylori Infection and Colorectal Cancer: Genetic Risk Links and Treatment Outcomes from Two Long-Term Randomized Trials

By MedXY 07/01/2026

Two large randomized trials reveal that Helicobacter pylori infection elevates colorectal cancer risk, particularly in individuals with specific bacterial virulence factors or high genetic susceptibility, and that eradication treatment may reduce this risk in selected groups.

Hematology-Oncology news Oncology

Unified Conditioning and GVHD Prophylaxis with Fludarabine, Cyclophosphamide, and 2 Gy TBI plus Post-Transplant Cyclophosphamide in Elderly AML/MDS Patients Undergoing Haploidentical or Unrelated Donor Allo-SCT

By MedXY 06/30/2026

Fludarabine, cyclophosphamide, and low-dose TBI combined with post-transplant cyclophosphamide provide a safe and effective single platform for haploidentical and unrelated donor allo-SCT in older AML/MDS patients, showing favorable survival and GVHD outcomes.

news Oncology Respiratory

Hypoxic Microenvironment Triggers Early Aggressive Progression in EGFR-Mutant Lung Adenocarcinoma

By MedXY 06/29/2026

This study reveals that hypoxia in centrally located EGFR-mutant lung adenocarcinomas drives an alveolar lineage imbalance via the ZAKα-MAPK-c-Fos pathway, promoting early tumorigenesis. Therapeutic oxygenation can restore lineage balance and limit aggressive progression.

General Surgery news Oncology

Refining Prognostic Assessment in Perihilar Cholangiocarcinoma: The Clinical Utility of Dual Radial Margin Distance Cutoffs

By MedXY 06/29/2026

This study identifies dual cutoff values of 0 and 1 mm for radial margin distance in perihilar cholangiocarcinoma, providing a simple and effective stratification tool for postoperative recurrence risk and survival prediction.

news OB/GYN & Women’s Health Oncology

PRO-PLATINUM Trial: Probiotic Modulation of the Microbiome to Enhance Outcomes in Ovarian Cancer Chemotherapy

By MedXY 06/29/2026

The PRO-PLATINUM trial evaluates a novel 5-strain probiotic's effect on gut and vaginal microbiome composition and clinical outcomes in ovarian cancer patients undergoing platinum chemotherapy, assessing safety, feasibility, and translational biomarkers.

Gastroenterology news Oncology

Strategic Sequencing of Systemic Therapies in Advanced Hepatocellular Carcinoma: Beyond the Second Line

By MedXY 06/28/2026

This article reviews evolving therapeutic sequences in advanced hepatocellular carcinoma, highlighting the integration of immune-based combinations, tyrosine kinase inhibitors, liver function preservation, and the emerging multidimensional CUSE framework to optimize patient outcomes beyond second-line treatment.

Diabetes & Endocrinology news Oncology

Erythrocytosis in Advanced Thyroid Cancer Therapy: Emerging Safety Concerns with Targeted Agents

By MedXY 06/28/2026

Erythrocytosis is an underreported hematologic side effect of targeted therapies in advanced thyroid cancers, notably RET inhibitors, occurring early and recurrently without impacting survival outcomes but correlating with disease control rate.

news Oncology Pathology & Lab Medicine

Long-Term Efficacy and ctDNA Dynamics in Early-Stage ERBB2-Positive Breast Cancer Treated with Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab: Insights from the DAPHNe Trial

By MedXY 06/28/2026

The DAPHNe trial demonstrates excellent 5-year outcomes for stage II–III ERBB2-positive breast cancer patients treated with an abbreviated neoadjuvant paclitaxel, trastuzumab, and pertuzumab regimen, with ultrasensitive ctDNA monitoring showing near-universal clearance post-therapy.

Gastroenterology news Oncology

Targeting NEK9 to Overcome Immunotherapy Resistance in Hepatocellular Carcinoma by Reprogramming the Tumor Microenvironment

By MedXY 06/27/2026

NEK9 upregulation in hepatocellular carcinoma promotes immune evasion by enhancing PD-L1 expression and recruiting suppressive myeloid cells. Novel NEK9 inhibitors synergize with PD-L1 blockade, remodeling the tumor microenvironment and improving antitumor immunity.

news OB/GYN & Women’s Health Oncology

Long-Term Outcomes and Durability of Exceptional Responses to PARP Inhibitors in Recurrent Platinum-Sensitive Ovarian Cancer

By MedXY 06/26/2026

This international study reveals that many patients with platinum-sensitive recurrent ovarian cancer achieve durable, progression-free survival exceeding 5 years on PARP inhibitors, even after treatment discontinuation, with a low risk of secondary hematologic malignancies.